Avalo Therapeutics, Inc. (AVTX)

Current Report Filed: 2026-05-05

Key Insights

Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial for abdakibart in moderate to severe hidradenitis suppurativa, a significant clinical milestone that could support regulatory advancement and market potential.
The company is trading on the Nasdaq Capital Market, indicating it is a smaller-cap biotech firm where positive clinical trial results can have material impact on stock valuation and investor sentiment.
The filing uses Item 8.01 (Other Events) rather than Item 2.02 (Results of Operations), suggesting this announcement does not include financial performance metrics but focuses on clinical progress for a key pipeline asset.

Insider Trading Filed: 2026-05-01

Key Insights

CFO Christopher Sullivan executed two separate stock sales totaling 16,915 shares on April 29-30, 2026, at prices ranging from $12.61 to $13.54, reducing his direct beneficial ownership to 423 shares.
The sales were conducted under a Rule 10b5-1 trading plan adopted on November 12, 2025, indicating pre-planned, systematic liquidation rather than opportunistic trading or response to negative news.
The relatively modest post-transaction ownership position (423 shares) suggests significantly reduced insider confidence and skin-in-the-game, which could signal concern about near-term stock performance or company fundamentals.

Current Report Filed: 2026-04-28

Key Insights

Avalo significantly reduced its contingent payment obligation from $15 million to a maximum of $18.125 million ($2.25M upfront + $5.125M option + $12.75M if option not exercised), providing near-term cash relief of $2.25M immediately due within 5 business days.
The company gained flexibility through a 90-day option to pay $5.125 million instead of the full $12.75 million milestone payment, potentially reducing total obligation by 60% if exercised before the Phase 3 milestone is achieved.
The upfront $2.25 million payment represents immediate cash outflow that will impact liquidity, while the contingent nature of remaining obligations ties future payments to Phase 3 trial initiation progress.
This amendment to the AlmataBio acquisition agreement (originally dated March 27, 2024) suggests potential financing pressures or strategic prioritization of cash preservation by the company.

Insider Trading Filed: 2026-04-08

Key Insights

The reporting person, Mittie Doyle, who is the Chief Medical Officer of Avalo Therapeutics, Inc. (AVTX), exercised 3,970 stock options and subsequently sold 3,970 shares of the company's common stock.
The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, indicating a pre-planned and systematic approach to the transactions.
The reporting person continues to hold 3,622 shares of the company's common stock directly, representing their ongoing ownership and commitment to Avalo Therapeutics.

Insider Trading Filed: 2026-04-01

Key Insights

The reporting person, Rita Jain, was granted 1,339 stock options on March 31, 2026 with an exercise price of $14.93 and a 10-year expiration date. This suggests the company is incentivizing an insider to hold a long-term stake.
The options granted to Rita Jain are fully vested, indicating the company has confidence in her leadership and performance.
The transaction price of $12.13 per option suggests the stock may be undervalued, as the exercise price is higher than the current market price.

Insider Trading Filed: 2026-04-01

Key Insights

The reporting person, Kevin Robert Lind, has been granted 1,370 stock options with an exercise price of $14.93 and a 10-year expiration date.
The stock options are 100% vested as of the transaction date of March 31, 2026, indicating the reporting person has an immediate interest in the company's stock performance.
The relatively large option grant size and full vesting suggest the reporting person may have a significant leadership role or ownership stake in Avalo Therapeutics, Inc.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Mitchell Chan, acquired 3,166 shares of common stock through the vesting of restricted stock units (RSUs) on March 28, 2026.
The RSUs were granted on August 13, 2024 and vest over a 3-year period, with 1/3 vesting each year on March 28.
After the reported transaction, the reporting person holds a total of 6,333 shares of common stock.

Insider Trading Filed: 2026-03-31

Key Insights

Samantha Truex, a director of Avalo Therapeutics, exercised 3,166 restricted stock units, indicating continued confidence in the company's prospects.
The vesting schedule of Truex's restricted stock units suggests a long-term commitment, with 1/3 of the award vesting annually over the next three years.
Insider transactions can provide insights into management's view of the company's valuation and future performance, which may be of interest to investors.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Aaron Kantoff, acquired 3,166 shares of common stock through the vesting of restricted stock units, indicating continued investment in the company.
The restricted stock units were granted in August 2024 and vest over a 3-year period, suggesting a long-term commitment to the company.
The reporting person's direct ownership of 6,333 shares following the transaction represents a modest increase in their stake, which could signal confidence in the company's prospects.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Gilla Kaplan, has acquired 3,166 shares of common stock through the vesting of restricted stock units, indicating potential insider confidence in the company.
Kaplan's total direct beneficial ownership of common stock has increased to 6,333 shares following the reported transaction.
The restricted stock units granted to Kaplan in August 2024 are scheduled to vest in three equal installments over the next three years, suggesting a long-term alignment of interests between Kaplan and the company.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Neil Garry Arthur, the Chief Executive Officer of Avalo Therapeutics, Inc., exercised 64,866 restricted stock units and sold 21,892 shares of common stock on March 28, 2026.
The reporting person still holds 90,114 shares of common stock, indicating continued insider ownership and commitment to the company.
The timing and size of the transaction suggests the reporting person may have positive long-term outlook on the company's prospects.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Christopher Ryan Sullivan, exercised 24,200 restricted stock units (RSUs) and sold 8,241 shares to cover tax withholding, indicating a net increase in his beneficial ownership of Avalo Therapeutics, Inc. (AVTX) common stock.
The RSU grant and vesting schedule suggest that Sullivan is a key executive at Avalo Therapeutics, with a long-term incentive to drive the company's performance.
The reported transaction price of $13.89 per share for the shares sold to cover tax withholding provides insight into the current market value of Avalo Therapeutics' stock.

Insider Trading Filed: 2026-03-31

Key Insights

The reporting person, Jonathan Goldman, exercised 3,166 restricted stock units (RSUs) on March 28, 2026, indicating potential insider confidence in the company's long-term prospects.
The vesting schedule of the RSUs, with one-third vesting annually over three years, suggests a long-term alignment of the reporting person's interests with those of the company and its shareholders.
The direct ownership of the common stock after the transaction suggests the reporting person's willingness to hold a significant stake in the company, which could be viewed positively by investors.

Current Report Filed: 2026-03-27

Key Insights

Two directors, Dr. Jonathan Goldman and Mitchell Chan, have decided not to stand for re-election to the Avalo Therapeutics board at the 2026 Annual Meeting. This represents a change in the company's leadership and board composition.
The directors' decisions are not due to any disagreement with the company's operations, policies, or practices, suggesting an amicable departure.
The departures may provide an opportunity for Avalo Therapeutics to add new directors and perspectives to the board, potentially signaling a strategic shift or refocus for the company.

Annual Report Filed: 2026-03-23

Key Insights

Avalo Therapeutics, Inc. reported a significant increase in revenue from its product Milliprex over the past two years, indicating potential growth for the company.
The company has been actively pursuing partnerships and acquisitions, including the Almata Bio transaction, which could provide opportunities for further product development and expansion.
Avalo Therapeutics has a substantial amount of non-current derivative liabilities and other liabilities, which could present financial risks if not properly managed.

Current Report Filed: 2026-03-23

Key Insights

Avalo Therapeutics reported its financial results for the year ended December 31, 2025, which may provide investors with insights into the company's recent performance and potential future outlook.
The filing does not appear to mention any material agreements, leadership changes, or earnings surprises, suggesting the update may not contain highly significant news for investors.
Without additional details on the company's financial results, revenue trends, or guidance, the overall significance of this filing may be limited for investors.

Insider Trading Filed: 2026-03-18

Key Insights

Mittie Doyle, the Chief Medical Officer, exercised 19,500 stock options at $12.65 and 5,992 stock options at $8.04, indicating confidence in the company's future performance.
Doyle then sold 25,492 shares at an average price of $16.15, likely taking some profits but still retaining a substantial stake in the company.
The stock options held by Doyle have vesting schedules that incentivize long-term commitment, with 25% vesting in the first year and the remainder over the next three years.

Insider Trading Filed: 2026-03-02

Key Insights

The reporting person, Jennifer Riley, acquired 95,000 stock options on 2026-02-26 as part of her role as Chief Strategy Officer of Avalo Therapeutics, Inc. (AVTX).
The stock options have an exercise price of $17.64 and vest over a 4-year period, indicating a long-term incentive alignment between Riley and the company.
This stock option grant suggests that the company is incentivizing key leadership to drive long-term value creation for shareholders.

Insider Trading Filed: 2026-03-02

Key Insights

Mittie Doyle, the Chief Medical Officer of Avalo Therapeutics, Inc. (AVTX), has been granted 105,000 stock options with an exercise price of $17.64 and a 10-year expiration date.
The stock options will vest over a 4-year period, with 25% vesting on February 26, 2027 and the remainder vesting in equal monthly installments over the following 3 years, subject to Doyle's continued service.
This insider grant of stock options suggests that the company is incentivizing its Chief Medical Officer to remain with the company and continue to drive its strategic initiatives.

Insider Trading Filed: 2026-03-02

Key Insights

The reporting person, Boyd Taylor, acquired a stock option for 95,000 shares of Avalo Therapeutics, Inc. (AVTX) common stock on February 26, 2026, with a strike price of $17.64 and a 10-year expiration date.
The stock option vests over a 4-year period, with 25% vesting on February 26, 2027 and the remaining 75% vesting in equal monthly installments over the following 3 years, subject to the reporting person's continued service.
This stock option grant represents a significant long-term incentive for the Chief Business Officer of Avalo Therapeutics, potentially aligning his interests with those of shareholders.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information